These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11591521)

  • 1. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.
    Smith RA; Barbosa J; Blum CL; Bobko MA; Caringal YV; Dally R; Johnson JS; Katz ME; Kennure N; Kingery-Wood J; Lee W; Lowinger TB; Lyons J; Marsh V; Rogers DH; Swartz S; Walling T; Wild H
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2775-8. PubMed ID: 11591521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.
    Khire UR; Bankston D; Barbosa J; Brittelli DR; Caringal Y; Carlson R; Dumas J; Gane T; Heald SL; Hibner B; Johnson JS; Katz ME; Kennure N; Kingery-Wood J; Lee W; Liu XG; Lowinger TB; McAlexander I; Monahan MK; Natero R; Renick J; Riedl B; Rong H; Sibley RN; Smith RA; Wolanin D
    Bioorg Med Chem Lett; 2004 Feb; 14(3):783-6. PubMed ID: 14741289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
    Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
    Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
    Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and discovery of small molecules targeting raf-1 kinase.
    Lowinger TB; Riedl B; Dumas J; Smith RA
    Curr Pharm Des; 2002; 8(25):2269-78. PubMed ID: 12369855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
    Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
    Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
    Lu C; Tang K; Li Y; Li P; Lin Z; Yin D; Chen X; Huang H
    Eur J Med Chem; 2014 Apr; 77():351-60. PubMed ID: 24675135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
    Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
    Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas.
    Temal T; Jary H; Auberval M; Lively S; Guédin D; Vevert JP; Deprez P
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2451-4. PubMed ID: 23465611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
    Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
    J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
    Holladay MW; Campbell BT; Rowbottom MW; Chao Q; Sprankle KG; Lai AG; Abraham S; Setti E; Faraoni R; Tran L; Armstrong RC; Gunawardane RN; Gardner MF; Cramer MD; Gitnick D; Ator MA; Dorsey BD; Ruggeri BR; Williams M; Bhagwat SS; James J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5342-6. PubMed ID: 21807507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
    Zhan W; Li Y; Huang W; Zhao Y; Yao Z; Yu S; Yuan S; Jiang F; Yao S; Li S
    Bioorg Med Chem; 2012 Jul; 20(14):4323-9. PubMed ID: 22721924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trisubstituted ureas as potent and selective mPGES-1 inhibitors.
    Chiasson JF; Boulet L; Brideau C; Chau A; Claveau D; Côté B; Ethier D; Giroux A; Guay J; Guiral S; Mancini J; Massé F; Méthot N; Riendeau D; Roy P; Rubin J; Xu D; Yu H; Ducharme Y; Friesen RW
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1488-92. PubMed ID: 21295979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
    Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel N
    Qi B; Yang Y; He H; Yue X; Zhou Y; Zhou X; Chen Y; Liu M; Zhang A; Wei F
    Eur J Med Chem; 2018 Feb; 146():368-380. PubMed ID: 29407963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.
    Thompson AM; Connolly CJ; Hamby JM; Boushelle S; Hartl BG; Amar AM; Kraker AJ; Driscoll DL; Steinkampf RW; Patmore SJ; Vincent PW; Roberts BJ; Elliott WL; Klohs W; Leopold WR; Showalter HD; Denny WA
    J Med Chem; 2000 Nov; 43(22):4200-11. PubMed ID: 11063616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
    Honma T; Hayashi K; Aoyama T; Hashimoto N; Machida T; Fukasawa K; Iwama T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Iwasawa Y; Hayama T; Nishimura S; Morishima H
    J Med Chem; 2001 Dec; 44(26):4615-27. PubMed ID: 11741479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor.
    Song EY; Kaur N; Park MY; Jin Y; Lee K; Kim G; Lee KY; Yang JS; Shin JH; Nam KY; No KT; Han G
    Eur J Med Chem; 2008 Jul; 43(7):1519-24. PubMed ID: 18023932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
    Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.